Onward Therapeutics and Biomunex Pharmaceuticals Enter into a Worldwide Exclusive License and Co-development Agreement to a Bispecific Antibody for Immuno-Oncology
Lausanne, Switzerland, February 16, 2021
–Onward Therapeutics SA (Onward) announced today the execution of a worldwide exclusive license and co-development agreement with Biomunex Pharmaceuticals SAS (Biomunex), Paris, France, of a bispecific antibody targeting two immune checkpoints.
Biomunex grants the rights for Onward to pursue development, manufacture and commercialization of this first-in-class bispecific antibody. Onward and Biomunex will jointly develop the antibody during
the preclinical and early clinical program. Biomunex is responsible for early preclinical development, while Onward will complete the IND-enabling studies, and will be responsible for GMP manufacture,
clinical development, and commercialization.
Read full press release